[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pfizer Inc (PFE)

Pfizer Inc (PFE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 140,890,256
  • Shares Outstanding, K 5,699,444
  • Annual Sales, $ 62,579 M
  • Annual Income, $ 7,771 M
  • EBIT $ 19,384 M
  • EBITDA $ 25,976 M
  • 60-Month Beta 0.34
  • Price/Sales 2.28
  • Price/Cash Flow 5.70
  • Price/Book 1.58

Options Overview Details

View History
  • Implied Volatility 22.50% (+1.69%)
  • Historical Volatility 18.70%
  • IV Percentile 20%
  • IV Rank 26.76%
  • IV High 34.15% on 10/10/25
  • IV Low 18.25% on 08/18/25
  • Expected Move (DTE 2) 0.36 (1.49%)
  • Put/Call Vol Ratio 0.72
  • Today's Volume 176,488
  • Volume Avg (30-Day) 120,470
  • Put/Call OI Ratio 0.91
  • Today's Open Interest 2,273,924
  • Open Int (30-Day) 2,547,526
  • Expected Range 23.68 to 24.40

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.68
  • Number of Estimates 6
  • High Estimate $0.72
  • Low Estimate $0.66
  • Prior Year $0.78
  • Growth Rate Est. (year over year) -12.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.92 +0.48%
on 06/24/26
26.53 -9.40%
on 05/27/26
-1.86 (-7.18%)
since 05/22/26
3-Month
23.92 +0.48%
on 06/24/26
28.75 -16.37%
on 04/02/26
-2.92 (-10.83%)
since 03/24/26
52-Week
23.11 +4.02%
on 08/01/25
28.75 -16.37%
on 04/02/26
-0.27 (-1.11%)
since 06/24/25

Most Recent Stories

More News
Pfizer Declares Third-Quarter 2026 Dividend

Board of Directors approves quarterly cash dividend of $0.43 per share

PFE : 24.04 (-2.75%)
FDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance

First and only CDK4/6 inhibitor approved for HR+ metastatic disease regardless of HER2 status Approval based on data from the collaborative Phase 3 PATINA...

PFE : 24.04 (-2.75%)
Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, August 4, 2026. The purpose...

PFE : 24.04 (-2.75%)
Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer

Pfizer Inc. (NYSE: PFE) today announced topline results from the Phase 3 SigVie-002 study (previously known as Be6A Lung-01) evaluating sigvotatug vedotin, an investigational, potential first-in-class...

PFE : 24.04 (-2.75%)
Pfizer Announces Chief Financial Officer Transition

Pfizer Inc. (NYSE: PFE) today announced that Dave Denton, Chief Financial Officer, will step down from his current role and leave the company on August 15 for a professional opportunity outside of the...

PFE : 24.04 (-2.75%)
These 3 Quality Stocks Will Make You Want to LEAP on Their Calls

Thursday’s unusual options activity had plenty to choose from. However, it was the LEAPS that were really worth considering for bullish investors. Of the 28 calls over 365 days, these three quality stocks...

SBUX : 103.53 (+2.45%)
NVO : 47.41 (-0.02%)
LLY : 1,117.26 (+0.92%)
PFE : 24.04 (-2.75%)
AMZN : 234.27 (+0.07%)
DIS : 101.12 (-2.33%)
Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion

GSK agreed to acquire Nuvalent for $10.6 billion, or $124 per share, a roughly 40% premium, to add two late-stage lung cancer assets and offset an impending patent cliff.

RHHVF : 411.8400 (+0.45%)
NUVL : 123.58 (+0.11%)
GSK : 51.09 (-1.88%)
PFE : 24.04 (-2.75%)
Nuvalent Stock Hits All-Time High Following GSK's Buyout Offer

Nuvalent shares soar as GSK announces a $10.6 billion buyout deal. But is it too late already to invest in NUVL stock?

NUVL : 123.58 (+0.11%)
RHHBY : 51.2300 (+1.75%)
GSK : 51.09 (-1.88%)
PFE : 24.04 (-2.75%)
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need

Approval expands HYMPAVZI use to now include people with hemophilia A or B ages 12 years and older with inhibitors and pediatric patients (ages 6 to 11 years) with or without inhibitors ...

PFE : 24.04 (-2.75%)
Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide

Results from multiple Phase 2b dose finding studies for berobenatide (PF’3944) highlight a potential first-in-class monthly GLP-1 receptor agonist (GLP-1 RA) peptide, and support the planned Phase 3...

PFE : 24.04 (-2.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

Relative Strength just crossed below 30%. The market has entered oversold territory.

See More Share

Business Summary

Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare...

See More

Key Turning Points

3rd Resistance Point 25.98
2nd Resistance Point 25.54
1st Resistance Point 24.79
Last Price 24.04
1st Support Level 23.61
2nd Support Level 23.17
3rd Support Level 22.42

See More

52-Week High 28.75
Fibonacci 61.8% 26.59
Fibonacci 50% 25.93
Fibonacci 38.2% 25.26
Last Price 24.04
52-Week Low 23.11

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.